Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Speaking at a Bernstein event hosted by U.S. MedTech Analyst Lee Hambright, Benjamin said Insulet now serves 26 countries, including 20 markets with Omnipod 5, and has developed manufacturing capacity intended to support growth. He said the company is on track to add more customers this year than the company had in total when he joined more than a decade ago.
Benjamin cited an estimated 1.8 million people in the U.S. living with Type 1 diabetes, with less than half using AID technology. He also pointed to approximately 2.5 million U.S. patients with insulin-intensive, or basal-bolus, Type 2 diabetes, of whom about 5% use AID technology. Globally, Insulet estimates that only about 25% of the nearly 4 million Type 1 diabetes patients in its served markets use AID.
Type 2 Retention Actions
Benjamin said Type 2 customers accounted for roughly 40% of Insulet’s new customer starts during the second quarter. While the company remains enthusiastic about the market opportunity, it identified higher-than-desired attrition during the first 90 days after initiation.
Insulet is pursuing four actions intended to improve conversion from an initial Omnipod start to a longer-term customer relationship:
- Improving sampling workflows, including confirming prescriptions, prior authorizations, coverage discussions and customer support arrangements.
- Adjusting field incentives to emphasize durable customer starts and early customer success.
- Scaling customer service and clinical retention teams to provide additional education and support during the first 90 days.
- Accelerating the broader rollout of Omnipod Discover, its digital health platform.
Benjamin said Insulet’s analysis indicates that retention remains strong after the first 90 days for both Type 1 and Type 2 customers. The company’s near-term focus is therefore on improving the transition from initial use to that 90-day milestone. Insulet plans to provide an update on the effort during its fourth-quarter call in February.
On the longer-term Type 2 market, Benjamin reiterated the company’s previous goal of increasing AID penetration among insulin-intensive Type 2 patients to 10% to 15% by 2028, from about 5% currently. He said the company sees potential for penetration beyond that range over time, noting that continuous glucose monitor penetration in the Type 2 insulin-intensive market is about 55%.
Digital Platform and Product Pipeline
Benjamin described Omnipod Discover as a two-part platform for clinicians and people with diabetes. The clinician-facing component is designed to provide information that can support more efficient patient visits. The patient-facing component sends weekly text-message links with personalized insights, educational information and suggestions based on a user’s recent experience.
More than 10,000 people in the U.S. are enrolled in the limited release, Benjamin said. He added that Insulet has observed improvements in clinical outcomes and retention among participants, although he did not provide detailed data. The company expects to complete the full market release between now and year-end, with new customers enrolled in the platform.
Benjamin also outlined Insulet’s development roadmap. He said the company’s second-generation Omnipod 5 algorithm, which offers a lower glucose target, and its FreeStyle Libre 3 Plus integration were launched earlier this year. Omnipod 6 is expected in 2027, following clearance of its algorithm and a planned submission for the complete system.
According to Benjamin, Omnipod 6 will include an updated AID algorithm designed to deliver more automated insulin with less bolus burden, expanded wear-location flexibility and a single, updatable pod design. The updatable pod is intended to simplify prescribing and enable software updates without requiring new hardware to be manufactured and distributed.
Insulet’s Type 2 fully closed-loop system is currently in a pivotal study, with enrollment progressing, Benjamin said. The company expects the system in 2028 and described it as designed to require no insulin-setting inputs from physicians and to allow patients to self-start in a manner similar to a continuous glucose monitor. Insulet expects the simpler model could help expand adoption among primary-care providers.
International Growth, Quality and Competition
International revenue grew more than 30% year over year through the second quarter, Benjamin said. He said approximately 75% of the company’s international DASH installed base has converted to Omnipod 5. As a result, Insulet expects less pricing and product-mix benefit from conversions in 2027, with volume growth expected to account for a greater portion of international expansion.
The company entered Spain with Omnipod 5 in July and expects that market to contribute to growth. It also plans to launch FreeStyle Libre 3 integration in Germany and Canada by year-end.
Benjamin said Insulet has addressed handling issues in its factories that could damage sensitive cannula components. The company reviewed manufacturing processes more broadly and implemented corrective actions, he said. Despite the disruption, Insulet did not miss a customer shipment, according to Benjamin.
Addressing prospective patch-pump competition, Benjamin said additional entrants could help expand the overall AID and patch-pump categories. He maintained that Insulet’s fully disposable, waterproof system, manufacturing scale, commercial organization and product pipeline position the company to sustain market leadership. He also said the pricing environment in the pharmacy channel remains stable, describing Insulet’s pricing as flat to slightly higher, with 2027 negotiations proceeding in line with expectations.
About Insulet (NASDAQ:PODD)
Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
